<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101335</url>
  </required_header>
  <id_info>
    <org_study_id>FCCC-02028</org_study_id>
    <secondary_id>CDR0000393574</secondary_id>
    <nct_id>NCT00101335</nct_id>
  </id_info>
  <brief_title>Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia</brief_title>
  <official_title>A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. The use of celecoxib may prevent or treat head and neck cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works&#xD;
      compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the clinical efficacy of celecoxib vs placebo, in terms of inducing regression&#xD;
           of oral leukoplakia lesions, in patients with hyperplastic or dysplastic oral&#xD;
           leukoplakia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effect of this drug in modulating multiple intermediate biomarkers (e.g.,&#xD;
           COX-2, PPARγ, or PPARδ) in normal and hyperplastic or dysplastic oral epithelia of these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the cost-effectiveness of this drug as a chemopreventative agent in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, cross-over study. Patients&#xD;
      are stratified according to the pathology of the leukoplakia lesion (dysplasia vs&#xD;
      hyperplasia). Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral celecoxib twice daily for 3 months.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily for 3 months. All patients undergo&#xD;
           biopsy. Patients then cross-over to the opposite treatment arm for 3 months.&#xD;
&#xD;
      In both arms, treatment continues in the absence of unacceptable toxicity or disease&#xD;
      progression.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27-60 patients (18-40 for study drug, 9-20 for placebo before&#xD;
      cross-over) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <condition>Precancerous Condition</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of oral leukoplakia with hyperplasia or dysplasia&#xD;
&#xD;
               -  Documented by baseline biopsy of oral lesions suspicious for leukoplakia&#xD;
&#xD;
               -  For patients using dentures over the past 6 months, only lesions located on the&#xD;
                  ventral-lateral tongue or floor of the mouth are allowed&#xD;
&#xD;
               -  No leukoplakia/hyperplasia secondary to mechanical irritation&#xD;
&#xD;
          -  No carcinoma in situ of the oral cavity&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (women) OR ≥ 11 g/dL (men)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST or ALT normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No known active ischemic cardiac disease by stress test or echocardiogram&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of gastrointestinal hemorrhage&#xD;
&#xD;
          -  No known gastrointestinal ulcers within the past 2 years unless there is documentation&#xD;
             of healed lesions by upper endoscopy&#xD;
&#xD;
          -  No active or suspected peptic ulcer disease&#xD;
&#xD;
          -  Negative stool guaiac test&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             treatment&#xD;
&#xD;
          -  No use of snuff or chewing tobacco within the past 2 months&#xD;
&#xD;
          -  No active invasive malignancy within the past 3 years except nonmelanoma skin cancer&#xD;
             or in situ carcinomas&#xD;
&#xD;
          -  No clinical evidence of chronic infectious disease&#xD;
&#xD;
          -  No clinical evidence of connective tissue disease&#xD;
&#xD;
          -  No known hypersensitivity (asthma, urticaria, or acute rhinitis induced by NSAIDs) to&#xD;
             aspirin or other NSAIDs&#xD;
&#xD;
          -  No known hypersensitivity to sulfonamides&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 6 months since prior chronic or frequent use of systemic glucocorticoids&#xD;
&#xD;
          -  No concurrent chronic or frequent use of systemic glucocorticoids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior chronic or frequent (&gt; 100 mg per day aspirin equivalent) use of nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs) for 7 of the past 14 days&#xD;
&#xD;
          -  At least 3 months since prior experimental therapy&#xD;
&#xD;
          -  No concurrent chronic or frequent use of NSAIDs&#xD;
&#xD;
               -  Cardioprotective doses of aspirin ≤ 100 mg daily are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul F. Engstrom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>tongue cancer</keyword>
  <keyword>oral leukoplakia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

